Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Hack Andrew A. F.	2. Issuer Name and Ticker or Trading Symbol DYNAVAX TECHNOLOGIES CORP [ DVAX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) C/O BAIN CAPITAL LIFE SCIENCES INVESTORS, 200 CLARENDON STREET	3. Date of Earliest Transaction (MM/DD/YYYY) 3/11/2020
(Street) BOSTON, MA 02116 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Right to Exchange	⁽¹⁾⁽²⁾	3/11/2020		A		1 ⁽¹⁾⁽²⁾		3/11/2020	2/12/2022	Preferred Warrants(Right to Buy)	2916.25 ⁽¹⁾⁽²⁾	$0.00	1 ⁽¹⁾⁽²⁾	I	See Footnotes ⁽¹⁾⁽²⁾⁽³⁾

Explanation of Responses:
(1)	On March 11, 2020, each of Bain Capital Life Sciences Fund, L.P. ("BCLS") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Life Sciences Entities") entered into a letter agreement with the Issuer that provides the Bain Life Sciences Entities with the right, on one occasion, to exchange all or any portion of the warrants to purchase an aggregate of 2,916,250 shares of the Issuer's common stock (each, a "Warrant") owned by the Bain Life Sciences Entities for one or more warrants (each, a "Preferred Warrant") to purchase shares of the Issuer's non-voting Series C Convertible Preferred Stock (the "Series C Preferred Stock"). Each share of Series C Preferred Stock will be convertible, at the option of the holder, into 1,000 shares of the Issuer's common stock.
(2)	(Continued from footnote 1) Each Preferred Warrant issued in exchange for a Warrant will have an exercise price of $4,500 per share of Series C Preferred Stock and will be exercisable for a number of shares of Series C Preferred Stock equal to (x) the number of shares of Common Stock for which the Warrant then remains exercisable, divided by (y) 1,000. The Warrants, the Series C Preferred Stock and the Series B Convertible Preferred Stock held by the Bain Life Sciences Entities each include provisions prohibiting exercise or conversion into the Issuer's common stock to the extent such exercise or conversion would result in beneficial ownership of the Issuer's common stock in excess of 9.99%.
(3)	Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLS, and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Hack Andrew A. F. C/O BAIN CAPITAL LIFE SCIENCES INVESTORS 200 CLARENDON STREET BOSTON, MA 02116	X